Literature DB >> 6883284

A comparison of short-course, low-dose and long-course, high-dose preoperative radiation for carcinoma of the bladder.

P W Scanlon, M Scott, J W Segura.   

Abstract

This retrospective study failed to detect a significant difference in survival rates between patients with bladder carcinoma who underwent cystectomy after short-course, low-dose radiation and those who underwent cystectomy after long-course, high-dose radiation. The authors were able to identify in the long-course--high-dose group a subset of patients with an unusually good prognosis, but this advantage was not reflected in survival rates. The value of the ability of the long-course--high-dose preoperative technique to identify a subgroup of patients with a relatively good survival rate remains to be determined. In terms of the current management of bladder cancer, this ability to identify a favorable subset of patients is probably not worth the cost and morbidity involved. If, however, adjuvant chemotherapy is to be considered, this ability might be valuable.

Entities:  

Mesh:

Year:  1983        PMID: 6883284     DOI: 10.1002/1097-0142(19831001)52:7<1153::aid-cncr2820520705>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

Review 1.  Pelvic complications after interstitial and external beam irradiation of urologic and gynecologic malignancy.

Authors:  P F Schellhammer; G H Jordan; A M el-Mahdi
Journal:  World J Surg       Date:  1986-04       Impact factor: 3.352

Review 2.  Invasive bladder cancer--possible future treatment considerations.

Authors:  R A Gardiner
Journal:  Urol Res       Date:  1986

3.  Clinical significance of DNA ploidy and S-phase fraction and their relation to p53 protein, c-erbB-2 protein and HCG in operable muscle-invasive bladder cancer.

Authors:  S D Fosså; A A Berner; A B Jacobsen; H Waehre; B Kvarstein; T Urnes; P Ogreid; T E Johansen; J Silde; J M Nesland
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.